Literature DB >> 413551

In vitro studies with hexamethylmelamine.

C J Rutty, T A Connors.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 413551     DOI: 10.1016/0006-2952(77)90446-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  21 in total

1.  Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.

Authors:  C J Rutty; I R Judson; G Abel; P M Goddard; D R Newell; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration.

Authors:  J Dubois; G Atassi; M Hanocq; F Abikhalil
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.

Authors:  C J Rutty; D R Newell; J R Muindi; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 4.  The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors:  C Erlichman; R C Donehower; B A Chabner
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 5.  Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors:  C R Lee; D Faulds
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

6.  Human central nervous system pharmacology of pentamethylmelamine and its metabolites.

Authors:  D J Stewart; J A Benvenuto; M Leavens; R G Smith; F Cabanillas; R S Benjamin; T L Loo
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

Review 7.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  Dose-dependent pharmacokinetics of PMM in the rat.

Authors:  T Colombo; L Torti; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

9.  Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines.

Authors:  K J Miller; R M McGovern; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 10.  Clinical pharmacokinetics of altretamine.

Authors:  G Damia; M D'Incalci
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.